# The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

> **NCT06479291** · NA · RECRUITING · sponsor: **Yunfeng Cheng** · enrollment: 126 (estimated)

## Conditions studied

- Immune Thrombocytopenia With Positive ANA Antibodies

## Interventions

- **DRUG:** Hydroxychloroquine Oral Tablet
- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT06479291
- **Lead sponsor:** Yunfeng Cheng
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2026-01
- **Final completion:** 2026-12
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2024-06-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479291, "The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06479291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*